文献速递儿童神经与发育行为

新诊断儿童抽动障碍单药治疗及共患病现状调查

[Investigation on the status of monotherapy for newly diagnosed tic disorders and its comorbidity in children].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2020-01-01

该调查于2019年2至8月向中国抽动障碍研究联盟110名儿科神经和精神科医生发放问卷,有效回收94份(86%),以5级评分比较单药M与总体M(Q1,Q3)判定优选、次选和不合适药物,总结新诊断儿童抽动障碍及其共患病的单药治疗选择。

要点

  • 轻度暂时性抽动障碍不推荐药物治疗。
  • 硫必利、阿立哌唑、可乐定和氟哌啶醇是多数类型抽动障碍的优选药物。
  • 共患强迫障碍、ADHD、睡眠障碍或焦虑抑郁时需针对性选药。

核心结论

  • 轻度暂时性抽动障碍一般不推荐药物治疗,其余类型抽动障碍优选药物主要有硫必利、阿立哌唑、可乐定和氟哌啶醇等。
  • 合并强迫障碍、ADHD、睡眠障碍、焦虑及抑郁障碍等共患病时需针对相应共患病选择不同药物。

研究设计与样本

  • 2019年2至8月对中国抽动障碍研究联盟110名小儿神经内科和儿童精神科医生进行电子问卷调查,有效问卷94份(86%)。
  • 应答医生中男37名(39%)、女57名(61%),年龄(48±10)岁,从事儿童抽动障碍工作年限(17±10)年。
  • 采用5级评分(1~5分,非常不合适~非常合适),以单药M与总体M(Q1,Q3)比较:单药M≥总体Q3为优选药物,总体Q1≤单药M<总体Q3为次选药物,单药M<总体Q1为不合适药物。

主要发现

  • 不伴共患病首次单药治疗中,轻度暂时性抽动障碍无推荐药物。
  • 不伴共患病时,可乐定、阿立哌唑和硫必利评分分别为4(3,4)、4(3,4)、4(4,5)分,可作为中度慢性抽动障碍[3(2,4)分]优选药物,轻度Tourette综合征首次推荐同中度慢性抽动障碍。
  • 不伴共患病第二次单药治疗时,中度暂时性、轻度慢性抽动障碍和重度TS均推荐阿立哌唑、硫必利、氟哌啶醇、舒必利、可乐定和托吡酯为优选药物。
  • 共患强迫障碍时,中度慢性抽动障碍和TS推荐阿立哌唑[4(3,5)分]、舍曲林[4(3,4)分]为优选药物,总体为3(3,4)分。
  • 共患ADHD时,托莫西汀和可乐定均为4(4,5)分,为重度暂时性抽动障碍、中度慢性抽动障碍和TS的优选药物,也为重度TS首选推荐;重度慢性抽动障碍共患ADHD推荐可乐定[5(4,5)分,总体4(3,5)分]。

关键数值与推荐

  • 轻度暂时性抽动障碍不推荐药物治疗。
  • 不伴共患病中度慢性抽动障碍和轻度TS首次治疗优选可乐定、阿立哌唑、硫必利。
  • 共患强迫障碍时中度慢性抽动障碍和TS优选阿立哌唑、舍曲林。
  • 共患ADHD时重度暂时性抽动障碍、中度慢性抽动障碍和TS优选托莫西汀、可乐定。
  • 共患睡眠障碍时轻度慢性抽动障碍和TS优选艾司唑仑[3(2,3)分];共患焦虑及抑郁障碍时所有类型抽动障碍均优选舍曲林。

临床怎么用

  • 临床对轻度暂时性抽动障碍可先不启用药物,避免过度治疗。
  • 对其他类型抽动障碍,可优先考虑硫必利、阿立哌唑、可乐定和氟哌啶醇等优选药物。
  • 评估共患病后按强迫障碍、ADHD、睡眠障碍、焦虑抑郁分别选择相应优选药物。

局限性

  • 调查基于医生问卷评分,反映的是医生用药经验而非患者疗效数据。
  • 有效问卷94份,样本量有限。
  • 未报告不同药物评分比较的统计学检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the status of monotherapy for newly diagnosed tic disorders and its comorbidity in children, so as to provide a reference for clinical medication. Methods: A questionnaire survey was conducted to collect the application experience of monotherapy for newly diagnosed tic disorders and comorbidities in 110 pediatric neurologists and psychiatrists from Chinese Tic Disorders Study Consortium from February to August in 2019. Doctors were asked to rate treatment options based on a rank 5-point scale with "1" least appropriate and "5" most appropriate. The drug evaluation index was based on the comparison of the median score of a single drug with the overall scores of all drugs in this disease (M (Q1, Q3)), single drug M ≥ overall Q3 was recommended as preferred drugs; overall Q1≤ single drug M < overall Q3 was considered as secondary drugs; single drug M < overall Q1 was considered as unsuitable drugs. Results: Among 110 electronic questionnaires, 94 (86%) were availably responded, responding doctors included 37 (39%) males and 57 (61%) females, the age of responding doctors was (48±10) years, and their working year was (17±10) years. In the investigation of the first and second monotherapy for newly diagnosed tic disorders in children without comorbidities, there were no preferred drugs for mild transient tic disorders. The scores of clonidine, aripiprazole and tiapride were 4 (3, 4), 4 (3, 4), 4 (4, 5) scores respectively, and were greater than overall scores (3 (2, 4) scores), so they could be recommended as the preferred drugs for moderate chronic tic disorders, the recommendation for initial mild Tourette syndrome (TS) treatment was the same as preferred drugs for moderate chronic tic disorders. Similarly, clonidine, aripiprazole, tiapride and haloperidol could be recommended as the preferred drugs for other kinds of tic disorders. As for the second monotherapy, the preferred drugs for moderate transient tic disorders, mild chronic tic disorders and severe TS were all aripiprazole, tiapride, haloperidol, sulpiride, clonidine and topiramate. While clonidine, aripiprazole, tiapride could be considered as preferred drugs for severe transient tic disorders, moderate to severe chronic tic disorders and mild to moderate tic disorders. In the investigation of monotherapy for newly diagnosed tic disorders in children with comorbidities, for moderate chronic tic disorders and TS comorbid with obsessive-compulsive disorder, aripiprazole (4 (3, 5) scores) and sertraline (4 (3, 4) scores) were preferred drugs,the median scores of which were all greater than overall scores (3 (3, 4) scores), they were also the preferred treatment for severe transient tic disorders and mild chronic tic disorders. For mild and moderate transient tic disorders, severe chronic tic disorders and TS comorbid with obsessive-compulsive disorder, aripiprazole, fluvoxamine, fluoxetine, haloperidol and sertraline were preferred drugs. When comorbid with attention deficit hyperactivity disorder (ADHD), severe transient tic disorders, moderate chronic tic disorders and TS, tomoxetine and clonidine were recommended as preferred drugs (both 4 (4, 5) scores), and tomoxetine and clonidine were also the preferred treatment for severe TS. For severe chronic tic disorders comorbid with ADHD, clonidine (5(4, 5) scores) was preferred drug, greater than overall scores (4 (3, 5) scores), while for mild and moderate transient tic disorders clonidine, tomoxetine, guanidine and methylphenidate were recommended as preferred drugs. For mild chronic tic disorders and TS comorbid with ADHD tomoxetine was preferred drug. When comorbid with sleep disorders, there were no preferred drugs for mild transient tic disorders; estazolam (3 (2, 3) scores) was the preferred drug for mild chronic tic disorders and TS comorbid with sleep disorders. For othe kind of tic disorders comorbid with sleep disorders, estazolam, melatonin and clonazepam were preferred drugs. When comorbid with anxiety and depressive disorders, for all kinds of tic disorders sertraline was recommended as preferred drugs, the median scores of sertraline were all (4 (3, 5) scores) in severe transient tic disorders, moderate to severe chronic tic disorders and moderate TS, and greater than overall scores (3 (3, 4) scores). While severe chronic tic disorders comorbid with anxiety and depressive disorders, fluvoxamine could also be chosen as preferred drugs. Conclusions: Drug therapy is not recommended for mild transient tic disorders, while tiapride, aripiprazole, clonidine, and haloperidol are mainly preferred drugs for the other kinds of tic disorders. Corresponding drugs should be selected when tic disorders are combined with obsessive-compulsive disorder, ADHD, sleep disorders, anxiety, depression, etc. 目的: 了解新诊断儿童抽动障碍及其共患病的单药治疗现状,为临床选择用药提供参考。 方法: 编制问卷,2019年2至8月对中国抽动障碍研究联盟110名小儿神经内科和儿童精神科医生就新诊断儿童抽动障碍及其共患病单药治疗的应用经验进行问卷调查。药物评价标准采用5级评分制,1~5分递增评分表达非常不合适~非常合适。药物评价指标以单个药物评分与该类病情下所有药物总体得分比较[M(Q1,Q3)],单药M≥总体Q3推荐为优选药物;单药M在总体Q1~<Q3视为次选药物;单药M<Q1为不合适药物。 结果: 调查共发出电子版调查问卷110份,回收有效问卷94份(86%)。在94名医生中,男37名(39%),女57名(61%),年龄(48±10)岁,从事儿童抽动障碍工作年限(17±10)年。在新诊断儿童抽动障碍不伴共患病首次和第二次单药治疗调查中,轻度暂时性抽动障碍均无推荐药物;可乐定、阿立哌唑和硫必利药物评分4(3,4)、4(3,4)和4(4,5)分,可作为中度慢性抽动障碍[3(2, 4)分]推荐优选药物,轻度Tourette综合征(TS)首次推荐优选药物同中度慢性抽动障碍;以此类推,可乐定、阿立哌唑、硫必利和氟哌啶醇可作为其余类型共同推荐的优选药物;第二次单药治疗时,中度暂时性、轻度慢性抽动障碍和重度TS均推荐阿立哌唑、硫必利、氟哌啶醇、舒必利、可乐定和托吡酯为优选药物;重度暂时性抽动障碍、中重度慢性抽动障碍和轻度TS共同推荐优选药物有可乐定、阿立哌唑、硫必利。在新诊断儿童抽动障碍合并共患病单药治疗调查中,中度慢性抽动障碍和TS共患强迫障碍[3(3,4)分]推荐优选药物为阿立哌唑[4(3,5)分]、舍曲林[4(3,4)分],这两种药物也是重度暂时性抽动障碍和轻度慢性抽动障碍共患强迫障碍优选药物,轻中度暂时性抽动障碍、重度慢性抽动障碍和TS共患强迫障碍推荐阿立哌唑、氟伏沙明、氟西汀、氟哌啶醇和舍曲林为共同优选药物。托莫西汀[4(4,5)分]、可乐定[4(4,5)分]为重度暂时性抽动障碍、中度慢性抽动障碍和TS共患注意缺陷多动障碍(ADHD)的推荐优选药物,也为重度TS的首选推荐药物,重度慢性抽动障碍共患ADHD推荐优选可乐定[5(4,5)分,总体4(3,5)分]。轻、中度暂时性抽动障碍共患ADHD推荐优选可乐定、托莫西汀、胍法辛和哌甲酯,轻度慢性抽动障碍和TS共患ADHD推荐优选托莫西汀。轻度暂时性抽动障碍共患睡眠障碍无推荐优选药物;轻度慢性抽动障碍和TS共患睡眠障碍共同推荐优选艾司唑仑[3(2,3)分],其余类型共患睡眠障碍均共同推荐优选药物艾司唑仑、褪黑素和氯硝西泮。所有类型抽动障碍共患焦虑及抑郁障碍均推荐优选舍曲林,其在重度暂时性抽动障碍、中重度慢性抽动障碍和中度TS均为4(3,5)分,总体均为3(3, 4)分。 结论: 轻度暂时性抽动障碍一般不推荐药物治疗,其余类型抽动障碍患儿推荐优选药物主要有硫必利、阿立哌唑、可乐定和氟哌啶醇等。如儿童抽动障碍合并强迫障碍、ADHD、睡眠障碍、焦虑及抑郁障碍等共患病,需针对相应的共患病选择不同的药物治疗。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Lu Q, Cui YH, Liu ZS, et al. [Investigation on the status of monotherapy for newly diagnosed tic disorders and its comorbidity in children]. Zhonghua Er Ke Za Zhi. 2020. PMID: 33120459. doi:10.3760/cma.j.cn112140-20200628-00671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。